The contemporary renaissance in psychiatric research has thrust unconventional psychoactive compounds into mainstream clinical dialogue. Across diverse territories spanning the United States, Canada, Brazil, Mexico, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, and Switzerland, medical investigators are re-evaluating agents once dismissed or heavily stigmatized. Among these, 3,4-methylenedioxymethamphetamine occupies a unique classification. A frequent […]